Clinical Trial Update: Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating aldosterone inhibition as a therapeutic strategy for Duchenne Muscular Dystrophy has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Snippet

Sponsor: Ohio State University | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: COMPLETED | Results posted: 2019-09-24